Skip to main content

Landos Biopharma, Inc.

LABPDelisted May 23, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001785345

Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding Landos Biopharma, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of LABP: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders3335+2
Shares22.7M22.7M−39.0K (−0.2%)
Value$261.4M$331.1M+$69.6M (+26.6%)

New holders (5)

Institutions that held Landos Biopharma, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to LABP in Q3 2021
InstitutionSharesValue% of portfolio
Cambridge Investment Research Advisors, Inc.18,831$275.0K0.00%
Jacobs Levy Equity Management, Inc18,174$265.0K0.00%
Renaissance Technologies LLC10,900$159.0K0.00%
Allworth Financial LP5,286$77.0K0.00%
Cahill Financial Advisors Inc100$1.00K0.00%

Sold out (3)

Institutions that held Landos Biopharma, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of LABP in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Tudor Investment Corp Et Al17,793$206.0K
Nuveen Asset Management, LLC10,219$118.0K
Wells Fargo & Company9,526$110.0K